New appointments at Amarantus Therapeutics
This article was originally published in Scrip
Executive Summary
Amarantus Therapeutics, a privately held US biotechnology company developing disease-modifying treatments that address the underlying cause of cell death, has named Vern Norviel corporate secretary and has also appointed Kenneth Coleman, chairman of Accelrys, and Gene Mancino, a founding partner of the life sciences executive search firm Mancino Burfield Edgerton, to its board of directors. Mr Norviel is currently a partner at Wilson Sonsini Goodrich & Rosati, where he leads the firm's patents and innovation counselling practice.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.